Chronic lymphocytic Leukemia Venetoclax in the First-Line with significant Survival Benefit

被引：0
|
作者：
Warpakowski, Andrea
机构：
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2021年 / 44卷 / 7-8期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：435 / 435
页数：1
相关论文
共 50 条
  • [41] Venetoclax for the treatment of chronic lymphocytic leukemia
    Gentile, Massimo
    Petrungaro, Annamaria
    Uccello, Giuseppina
    Vigna, Ernesto
    Recchia, Anna Grazia
    Caruso, Nadia
    Bossio, Sabrina
    De Stefano, Laura
    Palummo, Angela
    Storino, Francesca
    Martino, Massimo
    Morabito, Fortunato
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (11) : 1307 - 1316
  • [42] Venetoclax in the treatment of chronic lymphocytic leukemia
    Korycka-Wolowiec, Anna
    Wolowiec, Dariusz
    Kubiak-Mlonka, Aleksandra
    Robak, Tadeusz
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2019, 15 (05) : 353 - 366
  • [43] Venetoclax and obinutuzumab in chronic lymphocytic leukemia
    Fischer, Kirsten
    Al-Sawaf, Othman
    Fink, Anna-Maria
    Dixon, Mark
    Bahlo, Jasmin
    Warburton, Simon
    Kipps, Thomas J.
    Weinkove, Robert
    Robinson, Sue
    Seiler, Till
    Opat, Stephen
    Owen, Carolyn
    Lopez, Javier
    Humphrey, Kathryn
    Humerickhouse, Rod
    Tausch, Eugen
    Frenzel, Lukas
    Eichhorst, Barbara
    Wendtner, Clemens-M.
    Stilgenbauer, Stephan
    Langerak, Anton W.
    van Dongen, Jacque J. M.
    Boettcher, Sebastian
    Ritgen, Matthias
    Goede, Valentin
    Mobasher, Mehrdad
    Hallek, Michael
    BLOOD, 2017, 129 (19) : 2702 - 2705
  • [44] Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
    Herbert Eradat
    Current Hematologic Malignancy Reports, 2019, 14 : 469 - 476
  • [45] Venetoclax (Venclexta) for Chronic Lymphocytic Leukemia
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2016, 58 (1500): : 101 - 102
  • [46] Venetoclax for the Treatment of Chronic Lymphocytic Leukemia
    Eradat, Herbert
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2019, 14 (05) : 469 - 476
  • [47] Promise of the obinutuzumab, ibrutinib and venetoclax combination in the first line of high-risk chronic lymphocytic leukemia
    Stocker, Nicolas
    HEMATOLOGIE, 2022, 28 (02): : 107 - 108
  • [48] Complex evaluation of serum immunoglobulin levels in patients with chronic lymphocytic leukemia: Significant increase in IgA after first-line chemoimmunotherapy
    Vodarek, Pavel
    Ecsiova, Dominika
    Rezacova, Vladimira
    Soucek, Ondrej
    Simkovic, Martin
    Vokurkova, Doris
    Belada, David
    Zak, Pavel
    Smolej, Lukas
    CANCER MEDICINE, 2024, 13 (15):
  • [49] First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia
    Eichhorst, Barbara F.
    Busch, Raymonde
    Stilgenbauer, Stephan
    Stauch, Martina
    Bergmann, Manuela A.
    Ritgen, Matthias
    Kranzhoefer, Nicole
    Rohrberg, Robert
    Soeling, Ulrike
    Burkhard, Oswald
    Westermann, Anne
    Goede, Valentin
    Schweighofer, Carmen D.
    Fischer, Kirsten
    Fink, Anna-Maria
    Wendtner, Clemens M.
    Brittinger, Guenter
    Doehner, Hartmut
    Emmerich, Bertold
    Hallek, Michael
    BLOOD, 2009, 114 (16) : 3382 - 3391
  • [50] Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States
    Davids, Matthew S.
    Chatterjee, Anuja
    Ravelo, Arliene
    Shapouri, Sheila
    Manzoor, Beenish S.
    Sail, Kavita
    Van de Wetering, Gijs
    Hallek, Michael
    BLOOD, 2019, 134
12345